XML 21 R9.htm IDEA: XBRL DOCUMENT v3.25.1
REVENUE
 3 Months Ended
Mar. 31, 2025
Disclosure of disaggregation of revenue from contracts with customers [abstract]  
REVENUE REVENUE
An analysis of revenue is as follows:
Three months ended March 31,
20252024
US$’000US$’000
Revenue:
License revenue
License revenue - Novartis9,348 12,181 
License revenue - total9,348 12,181 
Collaboration revenue185,615 78,481 
Other revenue90 3,329 
Total Revenue195,053 93,991 

An analysis of revenue by geographic area is as follows. The revenue information is based on the locations of the customers.
Three months ended March 31,
20252024
US$’000US$’000
License and other revenue
United States of America9,348 15,369 
China90 141 
Total revenue and other revenue9,438 15,510 
Collaboration Revenue
United States of America158,942 70,109 
Europe26,673 8,372 
Total collaboration revenue185,615 78,481 
Total Revenue195,053 93,991 

An analysis of the timing of transfer of goods or services is as follows:
Three months ended March 31,
20252024
US$’000US$’000
Revenue at a point in time185,705 81,810 
Revenue over time*9,348 12,181 
Total Revenue195,053 93,991 
*All revenue streams are recognized at a point in time except for License Revenue for Novartis which is recognized over time.
The following table shows the deferred revenue which is included in contract liabilities for the periods presented:
March 31December 31
20252024
US$’000US$’000
Contract liabilities (Current)39,535 46,874 
Total39,535 46,874